Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

European Molecular Biology Laboratory

Savira Pharmaceuticals Gmbh

Werner Neidhart

Daniel Hunziker

Matthias Heinrich Nettekoven

Bernd Kuhn

Henri Ramuz

Philippe Pflieger

Aurelia Conte

Alexander Mayweg

Patrizio Mattei

Kurt E Amrein

Volker Breu

Jean Ackermann

Tanja Schulz-Gasch

Hasane Ratni

Roland Jakob-Roetne

Wolfgang Wostl

Holger Kuehne

Anja Limberg

Quirico Branca

Werner Mueller

Martine Clozel

Georges Hirth

Bjoern Bartels

Kaspar Burri

Hans G Richter

Marcel Muller

Ulrike Obst Sander

Jean-Marie Cassal

Bernd-Michael Loffler

Stanley Wertheimer

Jean-Marc Plancher

Simona Maria Ceccarelli

Michael Reutlinger

Bernd Buettelmann

Heinz Stadler

Markus Rudolph

Michael G Klug

Guido Galley

Rosa Maria Rodriguez Sarmiento

S&eacute;bastien Roux

Philippe Coassolo

Greta Vastakaite

Emmanuel Pinard

Eric Vieira

Helmut Heinrich Buschmann

Rainer Eugen Martin

Stephan Roever

Robert Narquizian

Sven Taylor

Thomas Luebbers

Jerome Hert

Stephen Cusack

Robert James Weikert

Sandra Steiner

Norbert Handler

Oliver Szolar

Andrea Wolkerstorfer

Hans P Marki

Karlheinz Baumann

Peter Weiss

Hans Peter Marty

Jérôme Charles Sarie

Franz-Ferdinand Roch

Marie-Paule Heitz

Georg Jaeschke

Luca Claudio Gobbi

Wolfgang Guba

Hans Peter Wessel

Robert Alan Goodnow, Jr

Walter Fischli

Annick Goergler

Rosa Maria Rodriguez-Sarmiento

Stephen Matthew Lynch

Albrecht Edenhofer

Tadakatsu Takahashi

Christian Schnider

Jianping Cai

Daniela Krummenacher

Eva-Maria Gutknecht

Marcel Gubler

Frank Dautzenberg

Marcel M Uller

Rolf Huber

Stadler Heinz

Jenri Ramuz

Bernd-Michael L Offler

Björn Bartels

Stephan Brugger

Stefan Berchtold

Alexander V Mayweg

Stephen M Lynch

The invention provides novel compounds having the general formula (I) wherein R, R, R, Rand W are as defined herein, compositions including the compounds and methods of using the compounds.

Phenoxymethyl derivatives

The present invention relates to a compound of formula I, HetAr is a five or six membered heteroaryl group, selected from wherein Ris hydrogen, halogen, lower alkyl, lower alkoxy or lower alkyl substituted by halogen, and may be the same or different, if two Roccur; Ris lower alkyl or a mono- or polydeutered derivative thereof, lower alkyl substituted by halogen or lower alkoxy, lower alkenyl unsubstituted or substituted by halogen, cycloalkyl or CH-cycloalkyl unsubstituted or substituted by halogen, heterocycloalkyl or CH-heterocycloalkyl unsubstituted or substituted by lower alkyl; Ris halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen or S(O)-lower alkyl; n is 1, 2 or 3; if n is &#x3e;1, then Rmay be the same or different; or to a pharmaceutically active acid addition salt thereof, to a racemic mixture or to its corresponding enantiomer and/or an optical isomer and/or stereoisomer thereof. The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome. 

Phenoxytriazoles

The present invention relates to a compound of formula I, 1-1 or 1-2 wherein Ris hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, lower alkoxy, or lower alkoxy substituted by halogen; Rmay be different if n=2 or 3 n is 1, 2 or 3 Ar is a six membered heteroaryl group, selected from wherein Ris hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen or lower alkoxy; Ris hydrogen or halogen; or to a pharmaceutically active acid addition salt thereof. The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome. 

Bicyclic heteroaryl derivatives

The present invention relates to a compound of formula (I), wherein Ris hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, lower alkoxy or lower alkoxy substituted by halogen; R may be the same or different, if n=2 or 3; n is 1, 2 or 3; m is 1, 2 or 3; Ar is a five or six membered heteroaryl group, selected from (II), (III), (IV) or (V) wherein Ris hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen or lower alkoxy; Ris hydrogen or halogen; -( ) m-is &#x2014;(CH)&#x2014; or to pharmaceutically active acid addition salts thereof. The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-in-farct dementia, dementia pugilistica or Down syndrome. 

Bridged piperidine derivatives

The present invention relates to compounds of formula  

Triazolopyridines

The present invention relates to a compound of formula I wherein  The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.

Fused pyrimidine derivatives

The present invention relates to compounds of formula I,   The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.

The present invention relates to a compound of formula (I), wherein Ris hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, lower alkoxy or lower alkoxy substituted by halogen; and Rmay be different if n is 2 or 3; Ris hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, CN, lower alkoxy or lower alkoxy substituted by halogen; X is CH or N; m is 1, 2 or 3; -( )is &#x2014;(CH)&#x2014;; n is 1, 2 or 3; Ar is a five membered heteroaryl group, selected from formula (A), (B), (C), (D), (E) or (F), wherein Ris hydrogen, methyl or chloro; Ris hydrogen or methyl; Ris F, Cl, CHFor CF; or to pharmaceutically active acid addition salts thereof. The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome. 

The present invention relates to compounds of formula  The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.

The present invention relates to a compound of formula wherein The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.

The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease

The invention provides novel compounds having the general formula (I) wherein R, R, R, R, R, Rand n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, liver diseases involving inflammation, steatosis and/or fibrosis, such as non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, metabolic syndrome, obesity, chronic inflammatory and autoimmune inflammatory diseases.

Aryl-quinoline derivatives

The invention provides novel compounds having the general formula (I) wherein R, R, R, R, W, A and B are as described herein, compositions including the compounds and methods of using the compounds.

Urea derivatives and their use as fatty-acid binding protein (FABP) inhibitors

Bicyclic thiophenylamide compounds

Growing community of inventors

Hagenthal-le-Bas, France

Werner Neidhart